glp 1 agonist and heart failure The effect of GLP-1 receptor agonists on cardiac remodeling in patients with preserved reduced ejection fraction: a systematic review and meta-analysis | Heart Failure Reviews The Cardiovascular Biology of Glucagon-like
Description
gallbladder events Safety database : Large, diverse population across SURPASS and SURMOUNT programs
Triple Agonists Adding glucagon agonism to GLP-1/GIP agonism creates triple agonists currently in clinical trials
By Robert Barrie
Conclusions The present review elucidates the physiological benefits of synthetic incretin-based medications, highlighting both their unprecedented clinical efficacy against T2D and obesity and their extensive non-target metabolic benefits against heart, kidney, and liver diseases
Eli Lilly's GLP-1 franchise is also seeing volume effects as patients switch to generics, offering an early look at how global patent expiries could affect GLP-1 economics
